GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Buyback Yield %

Cereno Scientific AB (OSTO:CRNO B) Buyback Yield % : -5.01 (As of Mar. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cereno Scientific AB's current buyback yield was -5.01%.


Cereno Scientific AB Buyback Yield % Historical Data

The historical data trend for Cereno Scientific AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Buyback Yield % Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.52 -16.98 -21.41 -7.20 -4.94

Cereno Scientific AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.20 -7.54 -5.72 -3.24 -4.94

Competitive Comparison of Cereno Scientific AB's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's Buyback Yield % falls into.



Cereno Scientific AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cereno Scientific AB's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 76.683) / 1553.332
=-4.94%

Cereno Scientific AB's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 76.683) / 1553.332
=-4.94%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Cereno Scientific AB Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines